Growth Metrics

Eli Lilly (LLY) Share-based Compensation (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 18.30%
Dec 31, 2025 -9.93%
Sep 30, 2025 -18.24%
Jun 30, 2025 20.00%
Mar 31, 2025 8.22%
Dec 31, 2024 6.83%
Sep 30, 2024 -36.90%
Jun 30, 2024 32.43%
Mar 31, 2024 32.06%
Dec 31, 2023 -44.02%
Sep 30, 2023 33.50%
Jun 30, 2023 23.09%
Mar 31, 2023 41.23%
Dec 31, 2022 9.17%
Sep 30, 2022 -7.60%
Jun 30, 2022 -8.81%
Mar 31, 2022 34.13%
Dec 31, 2021 -16.43%
Sep 30, 2021 -1.96%
Jun 30, 2021 7.49%
Mar 31, 2021 -2.62%
Dec 31, 2020 22.45%
Sep 30, 2020 -6.64%
Jun 30, 2020 6.96%
Mar 31, 2020 -12.01%
Dec 31, 2019 8.08%
Sep 30, 2019 -5.03%
Jun 30, 2019 4.88%
Mar 31, 2019 4.12%
Dec 31, 2018 6.28%
Sep 30, 2018 -2.42%
Jun 30, 2018 3.24%
Mar 31, 2018 -5.82%
Dec 31, 2017 3.29%
Sep 30, 2017 0.00%
Jun 30, 2017 0.87%
Mar 31, 2017 3.74%
Dec 31, 2016 8.62%
Sep 30, 2016 -5.38%
Jun 30, 2016 4.84%
Mar 31, 2016 6.16%
Dec 31, 2015 6.76%
Sep 30, 2015 -1.97%
Jun 30, 2015 14.11%
Mar 31, 2015 20.44%
Dec 31, 2014 5.45%
Sep 30, 2014 -0.26%
Jun 30, 2014 0.78%
Mar 31, 2014 -3.77%
Dec 31, 2013 9.64%
Sep 30, 2013 8.04%
Jun 30, 2013 -4.55%
Mar 31, 2013 -14.56%
Dec 31, 2012 19.42%
Sep 30, 2012 -1.15%
Jun 30, 2012 12.94%
Mar 31, 2012 -15.80%
Dec 31, 2011 0.55%
Sep 30, 2011 0.55%
Jun 30, 2011 -4.22%
Mar 31, 2011 -32.08%
Dec 31, 2010 19.23%
Sep 30, 2010 -13.97%
Jun 30, 2010 -26.19%
Mar 31, 2010 -29.20%
Dec 31, 2009 0.10%
Sep 30, 2009 10.29%
Jun 30, 2009 242.66%